ESMO - European Society for Medical Oncology’s Post

#health_equity means the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, and preferred language. While magnificent advances in the management of #patients suffering from #cancer have been introduced during the last decades and have improved the #survival_rates, most of these treatments are not easily available for patients from #developing countries...

A recent study by Christopher Willy Schwarz and colleagues presented at #EADV24 reveals insight into 𝐧𝐨𝐧-𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐬𝐰𝐢𝐭𝐜𝐡𝐞𝐬 between adalimumab products in patients with psoriasis. ✅ The risk of discontinuation was 0-8% within six months among 180 patients undergoing non-medical switches. 💉 The highest discontinuation rate was found for patients switching from the reference to a biosimilar drug. 🌍 The results are comparable with previous studies, thus adding to the growing evidence of the safety of adalimumab switches. 📸 Hear more about the exciting results at Dermatologi DK: https://lnkd.in/dcccBnu7

Many took the primary series in 2021 and still feel sick in 2024. Our published proposal that offers the best hope is McCullough Protocol Base Spike Detoxification. All OTC oral starting doses: 1) Nattokinase 2000 FU po BID 2) Bromelain 500 mg po QD 3) Curcumin/Bioperine 500/5 mg po BID In practice we add other agents to this base combination to manage post-acute sequelae arising from the two major S-protein exposures the population has incurred. Based on clinical observation we have recorded progress. No therapeutic claims can be made in the absence of large prospective, multi-drug, placebo-controlled trials. These take years to complete and as of today none are planned or registered. Reference: Hulscher N, Procter BC, Wynn C, McCullough PA. Clinical Approach to Post-acute Sequelae. Cureus. 2023 Nov 21;15(11):e49204. doi: 10.7759/cureus.49204. PMID: 38024037; PMCID: PMC10663976. Courtesy the American Moutsos, January 2024.

Clinical Reminder 👀 Gentamicin and Ototoxicity – Hearing the Warning Signs 🎧 Gentamicin, a powerful aminoglycoside antibiotic, carries a risk of ototoxicity, potentially causing irreversible hearing loss or balance disturbances. Who’s at risk? Patients with renal impairment or those on prolonged therapy are particularly vulnerable, as gentamicin levels can accumulate. Key Tip 🔑 Monitor renal function and perform regular audiometric testing in high-risk patients. Therapeutic drug monitoring (TDM) is essential to keep levels within a safe range. #Pharmacy #PharmX

🎉 Exciting News from argenx! 🎉 argenx announces the #approval of #VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Key Points: Approval: Granted by Japan’s Ministry of Health, Labour and Welfare (MHLW). Treatment: Once-weekly, 30-to-90 second subcutaneous injection, self-administered at home. Innovation: First and only neonatal Fc receptor (FcRn) blocker for CIDP. Efficacy: 69% of patients showed clinical improvement in the ADHERE trial. Impact: Provides a convenient and effective treatment option for CIDP patients in Japan. This marks a significant advancement in CIDP treatment, offering hope and improved quality of life for many patients. #Pharma #Biotech #Healthcare #CIDP #argenx #VYVDURA #Innovation #PatientCare Click Here for more info: https://lnkd.in/gSDNJDDp Click Here for Full Prescribing info: https://lnkd.in/gdq9EnzZ

💥SUN PHARMA and #Moebius Medical announced promising results from a clinical trial of their new treatment for knee osteoarthritis, MM-II.💥 Here are the key points: 🔺️ Significant Pain Reduction: Patients receiving a single intra-articular injection of MM-II experienced a 50% greater reduction in knee osteoarthritis pain compared to those who received a placebo. 🔺️Reduced Rescue Medication Usage: Those treated with MM-II also required less additional medication to manage their pain. 🔺️Durable Pain Relief: The pain relief from MM-II lasted up to 26 weeks post-injection. 🔺️Safety Profile: MM-II was found to be as safe as the placebo, with no significant adverse effects reported. 🔺️Next Steps: Sun Pharma and Moebius Medical plan to proceed with a Phase 3 clinical program and seek regulatory approvals in the European Union. These findings highlight MM-II's potential as an effective and long-lasting treatment option for knee osteoarthritis pain. #sunpharma #moebiusmedical #osteoporosis #MM #regulatory #approval #europeanunion #painrelief #eular

In an interview with The Clinical Trial Vanguard’s Moe Alsumidaie, Elysium Therapeutics, Inc. CEO Greg Sturmer discusses O2P, a groundbreaking path to #painrelief that’s designed to help reduce the risk of opioid misuse. #opioidoverdose #opioidepidemic #painmedication #opioidmisuse #elysiumtherapeutics #hydrocodone https://lnkd.in/eUnapmfJ

Developing advanced sustained-release dosage forms ensures consistent therapeutic effects, enhanced patient compliance, and optimized drug delivery. These systems are especially impactful in managing chronic conditions like cardiovascular diseases, where controlled, precise drug release can improve outcomes and quality of life. SmaBio Labs leverages cutting-edge formulation techniques and innovative release mechanisms to design solutions tailored to your molecule's unique properties. From concept to commercialization, we ensure efficiency and precision at every stage of development. Curious about the science behind sustained-release formulations and their role in cardiovascular therapies? Visit smabiolabs.com to explore the details. #SustainedRelease #DrugDelivery #CDMO #Innovation #SmaBioLabs #cardiovascularmedication

“This biomarker panel will improve our ability to measure and assess early acute kidney injury during drug development, leading to safer, more precise treatments.” - Steve Hoffmann, Programmatic Lead for the Kidney Safety Project at the Foundation for the National Institutes of Health. Find out more about the new urine biomarker panel that the FDA has recently endorsed: https://hubs.ly/Q033n5W80

Thanks to Moe Alsumidaie for his interview with Alex Greg Sturmer, CEO of Elysium Therapeutics, Inc., which was featured in The Clinical Trial Vanguard. Elysium is an emerging biopharmaceutical company that is establishing new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead SMART opioid product candidate – oral-overdose protected (O2P™) hydrocodone – is being developed for the treatment of moderate-to-severe acute pain. Elysium is also developing its SMART rescue medicine, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. https://lnkd.in/eGqSwPSM